QQQ   358.12 (-1.00%)
AAPL   163.84 (-0.41%)
MSFT   299.28 (-0.77%)
FB   313.29 (-1.03%)
GOOGL   2,671.53 (+0.20%)
AMZN   2,978.48 (-1.81%)
TSLA   976.23 (-2.01%)
NVDA   237.00 (-1.86%)
BABA   126.71 (-3.30%)
NIO   27.97 (-3.98%)
AMD   120.33 (-1.28%)
CGC   7.44 (-1.59%)
MU   82.54 (-2.97%)
GE   97.58 (-0.68%)
T   26.76 (-0.96%)
F   21.04 (-2.82%)
DIS   138.38 (-6.26%)
AMC   17.10 (-5.37%)
PFE   54.51 (+0.85%)
ACB   4.67 (-1.68%)
BA   207.98 (-2.90%)
QQQ   358.12 (-1.00%)
AAPL   163.84 (-0.41%)
MSFT   299.28 (-0.77%)
FB   313.29 (-1.03%)
GOOGL   2,671.53 (+0.20%)
AMZN   2,978.48 (-1.81%)
TSLA   976.23 (-2.01%)
NVDA   237.00 (-1.86%)
BABA   126.71 (-3.30%)
NIO   27.97 (-3.98%)
AMD   120.33 (-1.28%)
CGC   7.44 (-1.59%)
MU   82.54 (-2.97%)
GE   97.58 (-0.68%)
T   26.76 (-0.96%)
F   21.04 (-2.82%)
DIS   138.38 (-6.26%)
AMC   17.10 (-5.37%)
PFE   54.51 (+0.85%)
ACB   4.67 (-1.68%)
BA   207.98 (-2.90%)
QQQ   358.12 (-1.00%)
AAPL   163.84 (-0.41%)
MSFT   299.28 (-0.77%)
FB   313.29 (-1.03%)
GOOGL   2,671.53 (+0.20%)
AMZN   2,978.48 (-1.81%)
TSLA   976.23 (-2.01%)
NVDA   237.00 (-1.86%)
BABA   126.71 (-3.30%)
NIO   27.97 (-3.98%)
AMD   120.33 (-1.28%)
CGC   7.44 (-1.59%)
MU   82.54 (-2.97%)
GE   97.58 (-0.68%)
T   26.76 (-0.96%)
F   21.04 (-2.82%)
DIS   138.38 (-6.26%)
AMC   17.10 (-5.37%)
PFE   54.51 (+0.85%)
ACB   4.67 (-1.68%)
BA   207.98 (-2.90%)
QQQ   358.12 (-1.00%)
AAPL   163.84 (-0.41%)
MSFT   299.28 (-0.77%)
FB   313.29 (-1.03%)
GOOGL   2,671.53 (+0.20%)
AMZN   2,978.48 (-1.81%)
TSLA   976.23 (-2.01%)
NVDA   237.00 (-1.86%)
BABA   126.71 (-3.30%)
NIO   27.97 (-3.98%)
AMD   120.33 (-1.28%)
CGC   7.44 (-1.59%)
MU   82.54 (-2.97%)
GE   97.58 (-0.68%)
T   26.76 (-0.96%)
F   21.04 (-2.82%)
DIS   138.38 (-6.26%)
AMC   17.10 (-5.37%)
PFE   54.51 (+0.85%)
ACB   4.67 (-1.68%)
BA   207.98 (-2.90%)
NASDAQ:AMGN

Amgen Stock Forecast, Price & News

$231.43
+2.53 (+1.11%)
(As of 01/21/2022 09:52 AM ET)
Add
Compare
Today's Range
$228.51
$233.51
50-Day Range
$198.88
$235.36
52-Week Range
$198.64
$276.69
Volume
24,311 shs
Average Volume
2.54 million shs
Market Capitalization
$130.36 billion
P/E Ratio
23.83
Dividend Yield
3.04%
Beta
0.64
30 days | 90 days | 365 days | Advanced Chart
Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.


Amgen logo

About Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Headlines

The Top 3 Value Stocks to Buy Now (AMGN)
January 11, 2022 |  marketbeat.com
Amgen (AMGN) Stock Moves -1.04%: What You Should Know
January 20, 2022 |  finance.yahoo.com
1 Top Dividend Stock to Buy and Hold in 2022 and Beyond
January 13, 2022 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AMGN
CUSIP
03116210
Employees
24,300
Year Founded
1980

Sales & Book Value

Annual Sales
$25.42 billion
Cash Flow
$22.78 per share
Book Value
$16.16 per share

Profitability

Net Income
$7.26 billion
Pretax Margin
25.02%

Debt

Price-To-Earnings

Miscellaneous

Free Float
561,238,000
Market Cap
$130.36 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Ex-Dividend for 12/8 Dividend
11/15/2021
Dividend Payable
12/08/2021
Today
1/21/2022
Next Earnings (Estimated)
2/01/2022
Ex-Dividend for 3/8 Dividend
2/14/2022
Dividend Payable
3/08/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.70 out of 5 stars

Medical Sector

64th out of 1,418 stocks

Biological Products, Except Diagnostic Industry

10th out of 206 stocks

Analyst Opinion: 2.1Community Rank: 4.9Dividend Strength: 4.2Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Amgen (NASDAQ:AMGN) Frequently Asked Questions

Is Amgen a buy right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 2 sell ratings, 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Amgen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View analyst ratings for Amgen
or view top-rated stocks.

How has Amgen's stock price been impacted by COVID-19 (Coronavirus)?

Amgen's stock was trading at $198.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AMGN shares have increased by 15.9% and is now trading at $230.14.
View which stocks have been most impacted by COVID-19
.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, February 1st 2022.
View our earnings forecast for Amgen
.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) issued its quarterly earnings results on Tuesday, November, 2nd. The medical research company reported $4.67 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $4.22 by $0.45. The medical research company earned $6.71 billion during the quarter, compared to the consensus estimate of $6.70 billion. Amgen had a trailing twelve-month return on equity of 108.67% and a net margin of 21.77%. During the same period last year, the firm earned $4.37 earnings per share.
View Amgen's earnings history
.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Friday, December 3rd. Shareholders of record on Tuesday, February 15th will be given a dividend of $1.94 per share on Tuesday, March 8th. This represents a $7.76 annualized dividend and a dividend yield of 3.37%. The ex-dividend date of this dividend is Monday, February 14th. This is an increase from Amgen's previous quarterly dividend of $1.76.
View Amgen's dividend history
.

Is Amgen a good dividend stock?

Amgen pays an annual dividend of $7.04 per share and currently has a dividend yield of 3.04%. Amgen has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Amgen is 72.50%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Amgen will have a dividend payout ratio of 39.15% next year. This indicates that Amgen will be able to sustain or increase its dividend.
View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided EPS guidance of $16.500-$17.100 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.430. The company issued revenue guidance of $25.80 billion-$26.20 billion, compared to the consensus revenue estimate of $26.01 billion.

What price target have analysts set for AMGN?

19 analysts have issued 1-year target prices for Amgen's stock. Their forecasts range from $185.00 to $295.00. On average, they expect Amgen's share price to reach $232.24 in the next year. This suggests a possible upside of 0.9% from the stock's current price.
View analysts' price targets for Amgen
or view top-rated stocks among Wall Street analysts.

Who are Amgen's key executives?

Amgen's management team includes the following people:
  • Robert A. Bradway, Chairman, President & Chief Executive Officer
  • Esteban Santos, Executive Vice President-Operations
  • Peter H. Griffith, Chief Financial Officer & Executive Vice President
  • Mike Zahigian, Chief Information Officer & Senior Vice President
  • David M. Reese, Executive Vice President-Research & Development

What is Robert A. Bradway's approval rating as Amgen's CEO?

806 employees have rated Amgen CEO Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among Amgen's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Nordea Investment Management AB (0.67%), Sarasin & Partners LLP (0.24%), Coho Partners Ltd. (0.13%), Russell Investments Group Ltd. (0.07%), Retirement Systems of Alabama (0.04%) and Cullinan Associates Inc. (0.04%). Company insiders that own Amgen stock include David Piacquad, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends for Amgen
.

Which major investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Coho Partners Ltd., Russell Investments Group Ltd., Beacon Financial Group, Carnegie Capital Asset Management LLC, Arlington Financial Advisors LLC, Canton Hathaway LLC, and State of Alaska Department of Revenue. Company insiders that have sold Amgen company stock in the last year include Jonathan P Graham, Nancy A Grygiel, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen
or view top insider-selling stocks.

Which major investors are buying Amgen stock?

AMGN stock was bought by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Sarasin & Partners LLP, Stonnington Group LLC, Absher Wealth Management LLC, Brookstone Capital Management, Osher Van de Voorde Investment Management, Farmers & Merchants Investments Inc., and Kempner Capital Management Inc..
View insider buying and selling activity for Amgen
or or view top insider-buying stocks.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $230.14.

How much money does Amgen make?

Amgen has a market capitalization of $129.63 billion and generates $25.42 billion in revenue each year. The medical research company earns $7.26 billion in net income (profit) each year or $9.71 on an earnings per share basis.

How many employees does Amgen have?

Amgen employs 24,300 workers across the globe.

Does Amgen have any subsidiaries?

The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen (Europe) GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen Manufacturing Limited, Amgen Research (Munich) GmbH, Amgen Rockville Inc., Amgen S.A.S., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology (Ireland) Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Synergen, and Tularik.

When was Amgen founded?

Amgen was founded in 1980.

What is Amgen's official website?

The official website for Amgen is www.amgen.com.

Where are Amgen's headquarters?

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at (805) 447-1000, via email at [email protected], or via fax at 805-447-1010.


This page was last updated on 1/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.